BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 16140959)

  • 1. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
    Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
    Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.
    Ozoren N; Kim K; Burns TF; Dicker DT; Moscioni AD; El-Deiry WS
    Cancer Res; 2000 Nov; 60(22):6259-65. PubMed ID: 11103780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
    Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
    Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
    Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
    Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
    Izeradjene K; Douglas L; Delaney AB; Houghton JA
    Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
    Sylvester PW; Shah S
    Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
    Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L; Fang B
    Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.
    MacFarlane M; Harper N; Snowden RT; Dyer MJ; Barnett GA; Pringle JH; Cohen GM
    Oncogene; 2002 Oct; 21(44):6809-18. PubMed ID: 12360407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB; Bhardwaj U; Takada Y
    Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
    Song JH; Song DK; Herlyn M; Petruk KC; Hao C
    Clin Cancer Res; 2003 Sep; 9(11):4255-66. PubMed ID: 14519653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
    Johnsen JI; Pettersen I; Ponthan F; Sveinbjørnsson B; Flaegstad T; Kogner P
    Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FADD deficiency sensitises Jurkat T cells to TNF-alpha-dependent necrosis during activation-induced cell death.
    Lawrence CP; Chow SC
    FEBS Lett; 2005 Nov; 579(28):6465-72. PubMed ID: 16289096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N; El-Deiry WS
    Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.